Herpes Simplex Epidemiology Forecast 2025-2034

Herpes simplex virus (HSV) is a condition that results in painful blisters or ulcers. It majorly spreads through skin-to-skin contact. Although treatable, it is completely curable. The primary cause of oral herpes, herpes simplex virus type 1 (HSV-1), is thought to infect 3.8 billion people under 50 (64%) worldwide.

Herpes Simplex Epidemiology Forecast Report Coverage

The “Herpes Simplex Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of herpes simplex. It projects the future incidence and prevalence rates of herpes simplex across various populations. The study covers age and type as major determinants of the herpes simplex-affected population. The report highlights patterns in the prevalence of herpes simplex over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of herpes simplex in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Herpes Simplex: Disease Overview

Herpes simplex disease is a viral infection caused by the herpes simplex virus (HSV), which exists in two types, namely, HSV-1 (commonly causing oral herpes) and HSV-2 (mainly responsible for genital herpes). The virus spreads through direct contact with infected saliva, skin, or bodily fluids and can remain dormant in the body, leading to recurrent outbreaks. Symptoms include painful blisters, sores, itching, and flu-like symptoms in some cases. HSV is highly contagious, and while outbreaks can vary in frequency and severity, the virus remains in the body for life.

Herpes Simplex: Treatment Overview

The mode of treatment varies, depending upon the type of herpes. Episodic therapy includes targeting a single outbreak and involves taking medications to treat early symptoms such as itching or tingling. Antiviral medications such as Acyclovir, Famciclovir or Valacyclovir are approved the United States FDA. Episodic therapy can help in reducing symptoms, pain and helping in faster healing of sores. Chronic suppressive therapy is often recommended for genital HSV-2 as it is more severe than HSV-1. Healthcare providers recommend chronic suppressive therapy when the patient has been taking antiviral medicines for long and has been witnessing severe oral herpes outbreaks (about 6 in a year).

Epidemiology

The herpes simplex epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for herpes simplex by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for herpes simplex and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to data published by the World Health Organization (WHO), the primary cause of genital herpes, herpes simplex virus type 2 (HSV-2) infection, affects an estimated 520 million individuals aged 15 to 49 (13%) globally.
• In 2020, an estimated 205 million individuals between the ages of 15 and 49 (5.3%) had at least one genital herpes episode.
• Additionally, 92% of these individuals reported symptoms associated with an HSV-2 infection. HSV-2 is much more likely than genital HSV-1 infection to cause recurrent symptoms.
• Another study revealed that around 122 million new HSV-1 infections among people ages 0-49 occurred worldwide in 2020, including 16.8 million genitally acquired infections, for a total of 3.8 billion HSV-1-infected individuals. In 2.02 trillion and 17 million of these individuals, respectively, experienced at least one episode of HSV-2 or HSV-1 GUD.

Country-wise Herpes Simplex Epidemiology

The herpes simplex epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of herpes simplex varies significantly between countries due to differences in factors such as hygiene practices, healthcare infrastructure, antibiotic resistance patterns, and lifestyle behaviors, among others. In the United States, oral herpes (HSV-1), which results in fever, blisters or cold sores in or around the mouth, affects 50-80% of adult Americans. 1 in 6 Americans between the ages of 14 and 49 suffers from genital herpes, which is brought on by HSV-1 or HSV-2. Infections with genital herpes can manifest as blisters or sores, or they can be asymptomatic.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Herpes Simplex based on several factors.
• Herpes Simplex Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of herpes simplex are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of herpes simplex epidemiology in the 8 major markets?
• What will be the total number of patients with herpes simplex across the 8 major markets during the forecast period?
• What was the country-wise prevalence of herpes simplex in the 8 major markets in the historical period?
• Which country will have the highest number of herpes simplex patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of herpes simplex during the forecast period of 2025-2034?
• What are the currently available treatments for herpes simplex?
• What are the disease risks, signs, symptoms, and unmet needs of herpes simplex?

This product will be delivered within 3-5 business days.